MCT1 Double Nickase Plasmid (h): sc-400363-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- MCT1 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- MCT1 Double Nickase Plasmid (h) and MCT1 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting SLC16A1. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: MCT1 Antibody (H-1): sc-365501
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
MCT1 Double Nickase Plasmid (h) | sc-400363-NIC | 20 µg | $410.00 | |||
MCT1 Double Nickase Plasmid (h2) | sc-400363-NIC-2 | 20 µg | $410.00 |
SLC16A1 encodes monocarboxylate transporter 1 (MCT1), a proton-linked plasma membrane symporter that mediates bidirectional transport of lactate, pyruvate, and ketone bodies across the cell membrane. By coupling monocarboxylate flux to proton gradients, MCT1 regulates intracellular pH, redox balance, and metabolic crosstalk between glycolytic and oxidative cells, influencing pathways such as glycolysis, oxidative phosphorylation, and hypoxia-associated metabolic adaptation. MCT1 function is integrated with chaperone-dependent trafficking and stabilization at the membrane (e.g., CD147/BSG), affecting substrate availability and signaling in metabolically active tissues. Altered SLC16A1 expression or activity has been associated with dysregulated lactate handling and energy metabolism in cancer biology, skeletal muscle physiology, and neurological contexts, making it a relevant target for mechanistic studies of metabolic reprogramming.
MCT1 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the SLC16A1 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within SLC16A1. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt SLC16A1 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of SLC16A1-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.